A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

NCT04611802 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

33000

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV Infection
Covid19

Interventions

BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
OTHER: Placebo (Initial Vaccination Period)
BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)
OTHER: Placebo (Crossover Vaccination period)
BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)

Sponsor

Novavax

Collaborators

[object Object]